爱普塔集团
✦ 量化合理价值 计算方式说明
- 基于该股自身过去5年平均市盈率乘以滚动每股收益,推算出的合理价值区间为144.47-199.24。
- 当前价格比按平均倍数计算的合理价值(171.85)低27.5%。
估值 各估值倍数与自身5年区间的对比
同业对比 Medical Instruments & Supplies
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| 爱普塔集团 (ATR) | 7.92B | 22.47 | 3.01 | 1.52% |
| Intuitive Surgical (ISRG) | 150.74B | 48.93 | 8.30 | 0.00% |
| Becton Dickinson & Co (BDX) | 52.23B | 57.93 | 2.14 | 2.19% |
| ResMed (RMD) | 33.61B | 22.91 | 5.10 | 1.00% |
| Alcon (ALC) | 31.99B | 50.52 | 1.48 | 0.53% |
| Medline (MDLN) | 31.55B | 68.24 | 2.73 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价低于晨星合理价值估算16.1%。
合理价值
AptarGroup Inc is assigned a 5-star quantitative star rating, indicating our belief that this share class offers a compelling opportunity for investors. The stock currently trades at a 17% discount to our quantitative fair value estimate of $144.56 per share, which is reinforced by this estimate's low uncertainty rating.
The company's profitability strengthens our estimated fair value. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. For example, the firm's enterprise value to free cash flow ratio of 18.4 lies in the bottom 40% globally. This can be a sign of operational efficiency and potential for the company to fund growth, pay dividends, or reduce debt without needing additional capital. We believe this is a sign that shares could be cheap.
On a different note, the company's balance sheet is potentially concerning. Excessive leverage heightens financial risk, potentially undermining a firm's value. The firm's EBITDA/interest coverage ratio of 12.8, for example, ranks in the bottom 50% globally. This gives us pause, as it can be a warning sign of financial distress if conditions don't improve. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
经济护城河
The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.
作者:Quantitative Equity Report
报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
爱普塔集团 讨论区 0 条评论